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Reactive oxygen species (ROS) is a significant feature of atherosclerosis but the
impact of ROS on atherogenesis is not clear since antioxidants such as vitamin E
have little effect on atherosclerosis development in vivo. To investigate the role of
ROS in atherosclerosis, we used ApoE-deficient mice, and compared the treatment
effect of the antioxidant vitamin E with that of the angiotensin-converting enzyme
(ACE) inhibitor, captopril, because angiotensin II is a major source of ROS in the
vasculature. Dihydroethidium (DHE) staining demonstrated that vitamin E and captopril
both prevented the atherosclerosis-induced increase in aortic superoxide content.
In contrast, seven months of vitamin E treatment retarded the development of
atherosclerotic lesions by only 45.8 ± 11.5% whereas captopril reduced the aortic plaque
area by 88.1 ± 7.5%. To discriminate between vitamin E-sensitive and -insensitive
effects of ACE inhibition, we performed whole genome microarray gene expression
profiling. Gene ontology (GO) and immunohistology analyses showed that vitamin E
and captopril prevented atherosclerosis-related changes of aortic intima and media
genes. However, vitamin E did not reduce the expression of probe sets detecting
the aortic recruitment of pro-inflammatory immune cells while immune cell-specific
genes were normalized by captopril treatment. Moreover, vitamin E did not prevent the
atherosclerosis-dependent down-regulation of perivascular nerve-specific genes, which
were preserved in captopril-treated aortas. Taken together, our study detected antioxidant
vitamin E-like effects of angiotensin II inhibition in atherosclerosis treatment regarding
preservation of aortic intima and media genes. Additional vitamin E-insensitive effects
targeting atherosclerosis-enhancing aortic immune cell recruitment and perivascular nerve
degeneration could account for the stronger anti-atherogenic activity of ACE inhibition
compared to vitamin E.
Keywords: angiotensin II, angiotensin-converting enzyme, atherosclerosis, captopril, neuroprotection, oxidative
stress, perivascular nerve, vitamin E
INTRODUCTION
Increased generation of reactive oxygen species (ROS) is a promi-
nent feature of atherosclerosis development (Steinberg et al.,
1989; Ross, 1999). The vasoactive peptide angiotensin II was iden-
tified as a major trigger of ROS generation in the cardiovascular
system (Garrido and Griendling, 2009). Vice versa, inhibition
of the angiotensin II system reduced the generation of oxida-
tive stress in vitro and in vivo (Hayek et al., 1998; Wassmann
et al., 2004). Concomitantly, inhibition of angiotensin II gen-
eration or angiotensin II AT1 receptor antagonism/deficiency
retarded the development of atherosclerosis in animal models of
atherosclerosis and patients with cardiovascular disease (Hayek
et al., 1998; Yusuf et al., 2000; Abd Alla et al., 2004; Wassmann
et al., 2004). From those data it was concluded that angiotensin
II-dependent ROS generation contributed to the development of
atherosclerosis (Keidar, 1998; Hayek et al., 2003; Wassmann et al.,
2004).
On the other hand, the sole inhibition of ROS by antioxidants
and/or genetic tools showed varying results in animal models
of atherosclerosis (reviewed by Lönn et al., 2012). And clinical
studies did not detect any reliable effect of antioxidants on the
treatment or prevention of cardiovascular disease (reviewed by
Schramm et al., 2012). Nevertheless, many studies confirmed that
antioxidants had the potential to decrease the generation of ROS
in vitro and in vivo (Ozer et al., 1993; Suarna et al., 1993; Pratico
et al., 1998; Thomas et al., 2001; Gavrila et al., 2005). In view
of those conflicting results between cellular and animal models,
and clinical studies, the impact of ROS on the pathogenesis of
atherosclerosis is still not clear.
To study the interplay between angiotensin II and ROS dur-
ing the development of atherosclerosis, we applied hypercholes-
terolemic ApoE−/− mice, which are prone to atherosclerosis and
reproduce many features of atherosclerosis in patients (Piedrahita
et al., 1992; Plump et al., 1992). Moreover, increased ROS
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generation of ApoE−/− mice was confirmed by several studies
(Maor et al., 1997; Hayek et al., 1998). To inhibit the generation
of ROS, we used the antioxidant vitamin E, which is reported
to decrease ROS and also the development of atherosclerotic
plaques of ApoE−/− mice when fed a normal diet (Pratico et al.,
1998). The generation of angiotensin II was suppressed by the
angiotensin-converting enzyme (ACE) inhibitor captopril, which
has a well-established atherosclerosis-inhibitory activity in ani-
mal models and patients (Hayek et al., 1998; Abd Alla et al., 2004;
McMurray et al., 2006). Treatment effects of vitamin E and capto-
pril were compared by quantitative assessment of atherosclerotic
plaques and whole genome microarray gene expression profiling.
With this approachwe sought to identify differences between cap-
topril and vitamin E treatment, which could account for the weak
anti-atherosclerotic effect of vitamin E in vivo. Our study revealed
vitamin E-like effects of ACE inhibition regarding prevention of
atherosclerosis-induced alterations of the aortic intima andmedia
whereas aortic recruitment of pro-inflammatory immune cells
and neurodegeneration of perivascular nerves were not sensitive
to vitamin E treatment.
MATERIALS AND METHODS
ATHEROSCLEROSIS TREATMENT OF ApoE−/− MICE
The study was performedwith ApoE−/− mice on a B6 (C57BL/6J)
background similarly as described (Abd Alla et al., 2010). Mice
were kept on a 12 h light/12 h dark regime, had free access to food
andwater, and were fed a standard rodent chow containing 7% fat
and 0.15% cholesterol (AIN-93-based diet; without addition of
tocopherol acetate). As indicated, ApoE−/− mice (age 4–6 weeks)
were treated for 7 months without or with captopril in drinking
water (20mg/kg; dissolved fresh every day) or tocopherol acetate
(vitamin E, supplied in diet, 2000 IU/kg diet). A control group
of B6 mice was also included in the study. At an age of 32–34
weeks, all mice were anesthetized with ketamine and xylazine
(100/10mg/kg), perfused intracardially with sterile PBS, aortas
were isolated, rapidly dissected on ice and immediately frozen in
liquid nitrogen or processed for further use. Atherosclerotic lesion
area was quantified of oil red O-stained aortas by quantitative
image analysis.
All animal experiments were performed in accordance with
NIH guidelines, and reviewed and approved by the local commit-
tee on animal care and use (University of Zurich).
WHOLE GENOME MICROARRAY GENE EXPRESSION PROFILING
Whole genome microarray gene expression profiling was per-
formed essentially as described previously (Abd Alla et al., 2010).
Total RNA was isolated from aortic tissue of four groups of
mice: untreated ApoE−/− mice, captopril-treated ApoE−/− mice,
vitamin E-treated ApoE−/− mice and B6 mice. The RNA was
processed for whole genome microarray gene expression pro-
filing as described (Abd Alla et al., 2010). Fragmented, biotin-
labeled cRNA (15μg/gene chip) was hybridized to the gene chip
(Affymetrix GeneChip MG430 2.0 Array with more than 45,000
probe sets) in 200μl of hybridization solution in a Hybridization
Oven 640 (Affymetrix) at 45◦C for 16 h. GeneChips were washed
and stained using the Affymetrix Fluidics Station 450 accord-
ing to the instructions of the manufacturer. Microarrays were
scanned with the Affymetrix GeneChip Scanner 7G, and signals
were processed to a target value of 200 using GCOS (version
1.4, Affymetrix). Gene ontology (GO) analyses of microarray
data were performed with GCOS/RMA processed data using
GeneSpring GX software (Agilent). Data were compared between
groups using the unpaired two-tailed Student’s t-test. Probe
sets with significant difference (i.e., P ≤ 0.01 if not otherwise
stated, ≤−2-fold or≥+2-fold difference, with call present and/or
signal intensity ≥100) between treated ApoE−/− mice relative
to untreated ApoE−/− mice were used for GO classification.
Microarray data are available at the NCBI GEO database, acces-
sion numbers GSE19286 and GSE42813.
HISTOLOGY ANALYSES AND IMMUNODETECTION OF PROTEINS
For immunohistology analyses, we used aortic cryo-sections pre-
pared from vitamin E-treated, captopril-treated and untreated
ApoE−/− mice, and from B6 control mice. Isolated aortas of dif-
ferent groups were fixed with formalin (10% in PBS), dehydrated
and frozen at −80◦C. Frozen aortas were cut by a cryomicro-
tome (Microm). Aortic cryo-sections (10μm) taken at intervals
of 50μm were prepared of the ascending aorta between the aor-
tic sinus and aortic arch region, which is a highly susceptible
region for atherosclerotic lesion development. Prior to immuno-
histology analysis, antigen retrieval was performed by incubation
in retrieval buffer (4.2 g citric acid/2 L H2O, 0.05% Tween-20;
pH 6.0) and heating for 30min in a microwave. After washing
with PBS, the sections were incubated in H2O2 solution (3% in
PBS) for 5min, to inactivate endogenous peroxidases. After wash-
ing steps, sections were incubated in blocking buffer (5% bovine
serum albumin, 0.05% Tween-20 in PBS) for 1 h. Thereafter,
sections were incubated for 1 h at room temperature with the pri-
mary antibody (dilution 1:200 in blocking buffer), followed by
three washing steps with washing buffer (0.05% Tween-20 in PBS)
for 5min each to remove unbound antibody. After incubation
with the secondary antibody-peroxidase-conjugate against rabbit
[F(ab)2-fragments, dilution 1:500 in blocking buffer] followed by
washing steps, the detection of bound antibody was performed by
an enzyme-substrate reaction using DAB (3,3,‘diaminobenzidine
tetrahydrochloride) as substrate (DABEnhanced Liquid Substrate
System; Sigma). The following antibodies were used: anti-CCR9
(raised in rabbit against recombinant CCR9); anti-Cd8b (raised
in rabbit against a recombinant protein corresponding to amino
acids 22–175 of Cd8b); anti-neuropeptide Y (raised in rabbit
against recombinant neuropeptide Y); anti-Pln (raised in rabbit
against a peptide corresponding to amino acids 2–25 of Pln);
anti-SNAP25 (raised in rabbit against recombinant SNAP25);
anti-Sprr3 (raised in rabbit against recombinant Sprr3). Aortic
superoxide content was determined by dihydroethidium (DHE)
staining of aortic cryosections followed by quantitative assess-
ment of superoxide-generated fluorescence similarly as described
(Edwards et al., 2013). Quantification of immunohistology data
was done on four animals/group, using ten sections (10μm) per
mouse taken at intervals of 50μmof the ascending aorta between
the aortic sinus and aortic arch region, similarly as described (Abd
Alla et al., 2004). Quantitative assessment of aortic proteins by
immunoblotting was performed essentially as described (Fu et al.,
2013).
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For atherosclerotic lesion quantification, isolated aortas were
opened longitudinally, fixed in formalin (10% in PBS, 21 h) and
stained with oil red O. For oil red O staining, a stock solution of
oil red O (0.3 g oil red O in 10ml of 2-propanol) was prepared
and filtered (Whatman grade 1 filter paper). The stock solution
was freshly diluted 6:4 with H2O followed by sterile filtration
(0.2μm). For oil redO staining, formalin-fixed aortas were rinsed
with H2O and incubated with 2-propanol (70%). The internal
lumen of the pinned aortas was stained with the diluted oil red O
solution for 20min, followed by a brief incubation in 2-propanol
(70%) and rinsing with H2O. Oil red O-stained atherosclerotic
lesion area was quantified by image analysis with SigmaScan Pro
software.
Unpaired, two-tailed Student’s t-test was used to calcu-
late P-values. Analysis of variance was performed with Prism
(GraphPad). Statistical significance was set at a P-value of< 0.05,
unless indicated otherwise.
RESULTS
ANGIOTENSIN-CONVERTING ENZYME INHIBITION BY CAPTOPRIL OR
ANTIOXIDANT TREATMENT WITH VITAMIN E RETARDED THE
FORMATION OF ATHEROSCLEROTIC LESIONS IN ApoE−/− MICE
To investigate the antioxidant effect of angiotensin II inhi-
bition on atherosclerosis, we compared the treatment effect
of the ACE inhibitor captopril with that of the antioxidant
vitamin E. As disease model of atherosclerosis, we used hyper-
cholesterolemic ApoE−/− mice. After treatment for 7 months,
aortas were dissected and atherosclerotic lesion area of oil red O-
stained aortas was quantified of vitamin E-treated and captopril-
treated ApoE−/− mice relative to untreated ApoE−/− mice
(Figure 1A). Aortic lesion quantification showed that vitamin E
had retarded the development of atherosclerotic plaques lead-
ing to a decrease in atherosclerotic lesion area by 45.8 ± 11.5%
(Figures 1A,B). In agreement with previous data (Abd Alla et al.,
2010), angiotensin II inhibition by captopril had largely pre-
vented the development of atherosclerotic plaques of ApoE−/−
mice (Figure 1A), i.e., the atherosclerotic plaque area was reduced
by 88.1 ± 7.5% in captopril-treated mice compared to untreated
ApoE−/− mice (Figure 1B). As a control, captopril had signifi-
cantly reduced the systolic blood pressure of ApoE−/− mice from
130.8 ± 3.2mmHg to 114.6 ± 5.0mmHg whereas vitamin E had
no effect on blood pressure (Figure 1C).
ACE INHIBITION BY CAPTOPRIL AND VITAMIN E TREATMENT
PREVENTED THE INCREASE IN AORTIC SUPEROXIDE CONTENT OF
ApoE−/− MICE
We asked whether the aortic ROS production was affected by
captopril or vitamin E treatment. The aortic superoxide con-
tent was determined in situ by DHE staining, which reacts with
superoxide to form a fluorescent product, 2-hydroxyethidium
(Zhao et al., 2003; Edwards et al., 2013). Quantitative fluorescence
evaluation of DHE-stained aortic sections revealed a signifi-
cantly increased superoxide content of untreated ApoE−/− aortas,
i.e., superoxide-dependent fluorescence was increased 2.7 ± 0.4-
fold compared to B6 control mice (Figures 1D,E). In contrast,
vitamin E and captopril largely prevented the increase in aortic
ROS of ApoE−/− mice, because the fluorescence of DHE-stained
aortas from vitamin E- and captopril-treated ApoE−/− mice was
not significantly different from B6 control level (Figures 1D,E).
Thus, vitamin E and captopril both exerted antioxidant-like
effects in vivo, in atherosclerosis-prone ApoE−/− mice.
WHOLE GENOME MICROARRAY GENE EXPRESSION PROFILING OF
ATHEROSCLEROSIS TREATMENT WITH VITAMIN E AND CAPTOPRIL
REVEALED CONCORDANTLY REGULATED AORTIC GENES
To investigate gene expression changes induced by the treatment
of ApoE−/− mice with vitamin E and captopril, respectively, we
performed whole genomemicroarray gene expression profiling of
aortic tissue isolated from vitamin E-treated and captopril-treated
ApoE−/− mice relative to untreated ApoE−/− mice with promi-
nent atherosclerotic plaques. As a control, aortic tissue of healthy,
non-transgenic B6 mice was also analyzed. Gene expression data
showed a uniform quality of the hybridizedmicroarray gene chips
from four different groups of mice as evidenced by a comparable
number of probe sets present (Figure 2A). RNA integrity of all
groups was demonstrated by the comparable 3′/5′ signal intensity
ratios of probe sets detecting housekeeping genes such asGAPDH
(Figure 2A).
Data filtering was performed to detect significantly different
probe sets between treated and non-treated ApoE−/− mice. Data
filtering showed that vitamin E treatment had significantly altered
the signal intensity of 180 probe sets whereas ACE inhibitor
treatment with captopril had significantly altered 469 probe sets
(Figure 2B). Among significantly different probe sets, more than
30% of vitamin E-regulated probe sets, i.e., 58, showed con-
cordant regulation with probe sets affected by ACE inhibitor
treatment (Figure 2B, upper panel). On the other hand, 14%
of captopril-regulated probe sets showed concordant regulation
with probe sets regulated by vitamin E treatment (Figure 2B,
upper panel). Together these results indicate that a significant
proportion of ACE inhibitor-regulated probe sets are sensitive to
treatment with the antioxidant vitamin E.
Concordantly regulated genes between vitamin E-treated and
captopril-treated ApoE−/− mice could be of significant relevance
for the pathogenesis of atherosclerosis because more than 82%
(i.e., 48) of those commonly regulated probe sets were normal-
ized toward B6 control level (Figure 2B, lower panel). Among
concordantly regulated probe sets, which were normalized toward
B6 control level, 26 probe sets had significantly lower signal
intensities in untreated ApoE−/− aortas (Figure 3, upper panel)
whereas 22 probe sets showed a higher expression in untreated
ApoE−/− mice (Figure 3, lower panel). We focused on those
48 probe sets, which were normalized toward B6 control level,
to gain insight into mechanisms underlying the antioxidant-
sensitive component of atherosclerosis treatment by the ACE
inhibitor captopril.
VITAMIN E AND ACE INHIBITOR TREATMENT MAINTAINED THE
INTEGRITY OF AORTIC INTIMA GENES OF ATHEROSCLEROSIS-PRONE
ApoE−/− MICE
GO analysis was performed of concordantly up-regulated probe
sets from vitamin E- and captopril-treated ApoE−/− aortas.
GO analysis identified that the majority of genes with ≥2-fold
higher expression compared to untreated ApoE−/− aortas were
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FIGURE 1 | Angiotensin-converting enzyme inhibition by captopril and
antioxidant treatment with vitamin E retarded the formation of
atherosclerotic plaques in ApoE−/− mice. (A) Representative oil red
O-stained aortas isolated from a 34 week-old untreated B6 control mouse, a
34 week-old untreated ApoE−/− mouse, a vitamin E-treated ApoE−/− mouse
(+VitE), and an ACE-inhibitor-treated ApoE−/− mouse (+ACE-I). (B)
Atherosclerotic lesion area was quantified by quantitative image analysis of
oil red O-stained aortas isolated from 32–34 week-old ApoE−/− mice, vitamin
E-treated ApoE−/− mice and ACE-inhibitor-treated ApoE−/− mice (n = 12
mice/group; ∗∗∗P < 0.0001 vs. ApoE−/−). (C) Systolic blood pressure of
different treatment groups of mice (±s.d.; n = 5 mice/group; ∗∗∗P < 0.0001
vs. B6). (D) Detection of aortic ROS in situ by dihydroethidium (DHE) staining
of aortic sections and quantitative assessment of relative fluorescence levels
generated by reaction of dihydroethidium with superoxide (±s.d.; n = 5
mice/group; ∗∗∗P = 0.0006 vs. B6). (E) Representative DHE-stained aortic
sections from a 34 week-old untreated B6 control mouse, a 34 week-old
untreated ApoE−/− mouse, a vitamin E-treated ApoE−/− mouse (+VitE), and
an ACE-inhibitor-treated ApoE−/− mouse (+ACE-I); bar 200μm.
associated with stratified epithelium (Figure 4A). Moreover,
expression of those genes was normalized toward B6 control
level (Figure 4A). According to a previous study, genes associated
with stratified epithelium are characteristic of the aortic intima
and could protect the aortic intima against biomechanical stress
(Young et al., 2005).
Immunohistology analysis confirmed the microarray data for
small proline-rich protein 3 (Sprr3) as a typical gene, which was
more than 3-fold up-regulated by vitamin E (Figure 4B). Sprr3
showed prominent localization in the aortic intima and adja-
cent media of a vitamin E-treated and ACE inhibitor-treated
ApoE−/− mouse, respectively, whereas the Sprr3 protein was
barely detectable in the aorta of an untreated ApoE−/− mouse
(Figure 4B). Immunohistology also indicated that aortic Sprr3
was maintained at B6 control level by vitamin E and captopril
treatment (Figure 4B). Together these findings are compatible
with the notion that vitamin E treatment and ACE inhibitor
treatment protected the aortic intima of atherosclerosis-prone
ApoE−/− mice against ROS-mediated damage.
ANTIOXIDANT AND ACE INHIBITOR TREATMENT PRESERVED
THE CONTRACTILE PHENOTYPE OF AORTIC MEDIA
We also performed GO analysis of concordantly regulated
probe sets with low expression in treated ApoE−/− mice com-
pared to untreated ApoE−/− mice. GO analysis identified aor-
tic muscle-specific genes as the major category of probe sets
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FIGURE 2 | Whole genome microarray gene expression profiling of
atherosclerosis treatment with vitamin E and captopril revealed
concordantly regulated aortic genes. (A) Characteristics of aortic
microarrays used for data analysis. Two different gene chips are presented
of each study group. For each gene chip (Affymetrix GeneChip MG430 2.0
Array with more than 45,000 probe sets), RNAs from three different aortas
were pooled. (B) The upper panel presents a Venn diagram illustrating that
58 significantly different probe sets showed concordant regulation between
aortas isolated from vitamin E-treated (VitE) and captopril-treated (ACE-I)
ApoE−/− mice relative to untreated ApoE−/− mice. Probe sets with
significant difference (P ≤ 0.01; ≤−2-fold or ≥2-fold difference, signal
intensity ≥100 and/or call present) between vitamin E-treated and
non-treated ApoE−/− mice (180), and captopril-treated and non-treated
ApoE−/− mice (469) were identified and used for further analysis. The
lower panel illustrates that 82.8% (i.e., 48 probe sets) of concordantly
regulated probe sets between vitamin E- and captopril-treated ApoE−/−
aortas showed normalization toward B6 control level.
FIGURE 3 | Identification of atherosclerosis-related aortic genes of
untreated ApoE−/− mice, which were normalized by vitamin E (VitE)
and ACE inhibitor (ACE-I) treatment toward B6 control level. The first
panel presents a heat map of genes with low expression in untreated
ApoE−/− aortas, and the second panel presents probe sets with high
expression in untreated ApoE−/− mice (P ≤ 0.01, and ≥2-fold, or ≤−2-fold
difference).
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FIGURE 4 | Vitamin E and ACE-inhibitor treatment maintained the
integrity of aortic intima genes of atherosclerosis-prone ApoE−/−
mice. (A) Microarray gene expression data of concordantly regulated
genes with high expression in vitamin E-treated (VitE) and ACE-inhibitor
treated (ACE-I) ApoE−/− aortas relative to untreated ApoE−/− mice
(≥2-fold higher signal intensity; P ≤ 0.01) and normalization toward B6
control level. GO analysis classified the majority of those genes with
high expression as stratified epithelial genes of the aortic intima, which
could preserve the biomechanical barrier function of the aortic intima.
Relative gene expression of concordantly regulated genes is presented
as—fold of untreated ApoE−/− mice. (B) Left panels:
immunohistological detection of Sprr3 with anti-Sprr3 antibodies
validated microarray data and showed down-regulation of Sprr3 in the
aorta of a 34 week-old untreated ApoE−/− mouse relative to an
age-matched B6 mouse (upper panels). The Sprr3 protein was
preserved by vitamin E treatment and ACE-inhibitor treatment (lower
panels). Nuclei were counterstained with hematoxylin, HE (bar: 40μm).
The right panel shows quantitative evaluation of immunohistology data
from four mice each (±s.d.; n = 4; aP = 0.0029; bP = 0.0014;
cP = 0.0015 vs. ApoE−/−).
(12 probe sets), which showed a significantly lower expres-
sion in treated ApoE−/− mice relative to untreated ApoE−/−
mice (Figure 5A). Notably, vitamin E and captopril pre-
served most aortic media-specific genes at B6 control level
(Figure 5A).
Microarray data were confirmed by immunohistology anal-
ysis, which demonstrated the significant up-regulation of the
muscle-specific phospholamban (Pln) in the ascending aorta
of untreated ApoE−/− mice (Figure 5B). In contrast, phos-
pholamban staining was near B6 control level in vitamin
E-treated and captopril-treated aortas (Figure 5B). Moreover,
immunohistology analysis of phospholamban detected the pro-
liferation of phospholamban-positive smooth muscle cells in
the aortic media of the atherosclerotic aorta (Figure 5B). This
finding is significant because proliferation of vascular smooth
muscle cells is a characteristic feature of atherogenesis mark-
ing the transition of the contractile phenotype of aortic smooth
muscle cells to the synthetic phenotype (Denger et al., 1999).
Thus, antioxidant-like effects of the ACE inhibitor captopril
could prevent the switch from the contractile to the syn-
thetic phenotype of smooth muscle cells within the aortic
media.
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FIGURE 5 | Vitamin E and ACE inhibitor treatment preserved the
contractile phenotype of the aortic media. (A) Microarray gene
expression data of concordantly regulated genes with low expression in
vitamin E-treated (VitE) and ACE inhibitor-treated (ACE-I) ApoE−/− aortas
(≤−2-fold lower signal intensity than that of untreated ApoE−/− aortas;
P ≤ 0.01) and normalization toward B6 control level. GO analysis classified
the majority of those genes with low expression as aortic muscle genes of
the aortic media, which indicates that vitamin E and ACE-inhibitor treatment
could prevent the atherosclerosis-related transition of the contractile
phenotype of aortic smooth muscle cells to the synthetic phenotype.
Relative gene expression of concordantly regulated genes is presented
as—fold of untreated ApoE−/− mice. (B) Left panels: immunohistological
detection of phospholamban (Pln) with anti-Pln antibodies validated
microarray data and showed up-regulation of Pln in the ascending aorta of a
34 week-old untreated ApoE−/− mouse relative to an age-matched B6
mouse, a vitamin E-treated ApoE−/− mouse and an ACE-inhibitor-treated
ApoE−/− mouse (bar: 100μm; nuclei were counterstained with
hematoxylin, HE). The right panel shows quantitative evaluation of
immunohistology data from four mice each (±s.d.; n = 4; aP = 0.0004;
bP = 0.0001; cP = 0.0003 vs. ApoE−/−).
PRO-INFLAMMATORY IMMUNE CELL RECRUITMENT INTO THE
ATHEROSCLEROSIS-PRONE AORTA WAS SENSITIVE TO ACE
INHIBITION BUT INSENSITIVE TO VITAMIN E TREATMENT
Angiotensin II AT1 receptor activation exerts a major pro-
atherogenic role by stimulating the recruitment of pro-
inflammatory immune cells into the atherosclerosis-prone aorta
(Abd Alla et al., 2004, 2010; Cassis et al., 2007; Fukuda et al.,
2008). To decipher the impact of ACE inhibitor treatment ver-
sus vitamin E treatment on immune cell recruitment, microarray
data were filtered according to the following criteria: (1) sig-
nificantly lower gene expression in captopril-treated compared
to untreated ApoE−/− mice (P ≤ 0.05 and ≤−2-fold down-
regulation), (2) membrane localization, and (3) immune cell
specificity according to GO analysis. Data filtering identified
T cell- and macrophage-specific membrane proteins, which were
significantly reduced by captopril treatment toward B6 con-
trol level whereas markers of atheroprotective B cells were not
decreased (Figure 6A; and Abd Alla et al., 2010). These findings
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confirm that the recruitment of pro-inflammatory T cells and
macrophages into the atherosclerosis-prone aorta of ApoE−/−
mice is enhanced by angiotensin II and can be reduced by ACE
inhibition (Abd Alla et al., 2010).
In contrast to captopril, antioxidant treatment with vitamin
E did not significantly decrease immune-cell-specific markers in
the atherosclerosis-prone aorta (Figure 6A). Immunohistology
analysis confirmed the microarray data for the pro-atherogenic
T cell and macrophage-resident chemokine receptor 9, Ccr9
(Figure 6B). Vitamin E treatment did not prevent the appear-
ance of Ccr9-positive cells in the atherosclerosis-prone aorta of
ApoE−/− mice whereas the aorta of captopril-treatedmice resem-
bled the B6 control and did not show significant Ccr9-positive
cells (Figure 6B).
In agreement with inhibition of the aortic recruitment of pro-
inflammatory T cells by captopril, ACE inhibitor treatment with
captopril prevented the atherosclerosis-related increase in the aor-
tic content of the T cell-specific Cd8b protein of ApoE−/− mice
as determined by immunoblotting (Figure 6C). In contrast, vita-
min E treatment did not significantly change the amount of Cd8b
protein in the atherosclerosis-prone aorta of ApoE−/− mice com-
pared to untreated ApoE−/− mice (Figure 6C). Together these
findings present strong evidence that the recruitment of pro-
inflammatory immune cells into the aorta of ApoE−/− mice is
enhanced by angiotensin II and sensitive to ACE inhibition but
insensitive to vitamin E treatment.
ACE-INHIBITION PREVENTED THE ATHEROSCLEROSIS-RELATED
DOWN-REGULATION OF PERIVASCULAR NERVE-SPECIFIC GENES OF
ApoE−/− MICE
Cardiovascular diseases involving atherosclerosis, hypertension
or diabetes are reported to cause perivascular nerve deficits,
which finally lead to perivascular nerve degeneration (Webster
et al., 1991; Scott et al., 1992; Verbeuren et al., 1994; Hobara
et al., 2005). In view of those studies, we asked whether
hypercholesterolemic ApoE−/− mice also develop perivascular
nerve degeneration. To identify significantly altered nerve-specific
genes, GO analysis was performed searching for genes associ-
ated with a neuron-specific component (e.g., dendrite, myelin
sheath, or neuronal cell body) and/or the process of neuronal
system development. That approach identified 30 significantly
altered neuron/nerve-specific probe sets, which were significantly
down-regulated more than 2-fold in the atherosclerotic aorta
of untreated ApoE−/− mice relative to B6 controls (Figure 7A).
Thus, the aorta of atherosclerosis-prone ApoE−/− mice is char-
acterized by a significant down-regulation of neuron-specific
genes, which could reflect the development of perivascular nerve
degeneration.
Angiotensin II inhibition is reported to prevent perivascu-
lar nerve degeneration in spontaneously hypertensive rats with
excessive angiotensin II generation (Hobara et al., 2005). Since
hypercholesterolemia also triggers the release of angiotensin II
(Daugherty et al., 2004), we asked whether captopril treatment
prevented the down-regulation of neuron-specific genes in hyper-
cholesterolemic ApoE−/− mice. Microarray gene expression pro-
filing showed that ACE-inhibition prevented the down regulation
of all atherosclerosis-associated nerve-specific genes (Figure 7A).
In contrast to ACE inhibition, treatment with vitamin E did not
substantially affect those nerve-specific genes (Figure 7A).
Microarray data on the atherosclerosis-related down-
regulation of nerve-specific genes were validated by immunoblot
detection of the synaptosomal-associated 25 kDa protein
(Snap25) as a neuronal synapse-specific protein. Immunoblot
detection revealed that the Snap25 protein level was reduced by
56.1% in aortic tissue of untreated ApoE−/− mice compared to
B6 control aortas whereas the aortic content of Snap25 protein of
captopril-treated ApoE−/− mice was preserved at B6 control level
(Figure 7B). In contrast to captopril, vitamin E did not prevent
the atherosclerosis-related decrease of the aortic Snap25 protein
content (Figure 7B).
Neuropeptide Y (Npy) is present in all sympathetic nerves
innervating the cardiovascular system (Zukowska-Grojec et al.,
1998). Npy and other sympathetic nerve-associated genes [e.g.,
dopamine β-hydroxylase (Dbh), dopa decarboxylase (Ddc),
and norepinephrine transporter (Slc6a2)] were also among
those genes, which showed significant down regulation in the
atherosclerotic aorta of ApoE−/− mice, indicating that perivas-
cular nerve degeneration could affect peripheral sympathetic
nerves (Figure 7A). To validate microarray data of sympathetic
nerve-associated genes, we performed immunohistological detec-
tion of Npy. Immunohistology analysis of the neuron-specific
Npy confirmed the microarray data and showed that Npy-
positive neurons were decreased by 58.1% in the atheroscle-
rotic ApoE−/− aorta compared to the B6 control (Figure 7C).
Moreover, captopril treatment maintained the presence of Npy-
positive neurons in the aortic adventitia whereas the appearance
of Npy-positive neurons was significantly reduced in the vitamin
E-treated aorta (Figure 7C). Together these findings strongly
suggest that atherosclerotic ApoE−/− mice develop perivascular
nerve degeneration, which is sensitive to angiotensin II inhibition
but insensitive to vitamin E treatment.
DISCUSSION
Exaggerated generation of ROS is considered to affect major
processes during the pathogenesis of atherosclerosis. However,
the full impact of ROS on atherogenesis is not clear because
inhibition of ROS generation by genetic or pharmacological
tools has only modest effects in animal models or patients with
atherosclerosis (Lönn et al., 2012; Schramm et al., 2012). To
further investigate the role of ROS in atherogenesis, we used
atherosclerosis-prone hypercholesterolemic ApoE−/− mice, and
performed treatment with the antioxidant vitamin E. The treat-
ment effect of vitamin E was compared with that of the ACE
inhibitor captopril because angiotensin II is an important con-
tributor to ROS in the vasculature and cardiovascular system
(Garrido and Griendling, 2009). Moreover, the anti-atherogenic
potential of ACE inhibitors is well established in animal mod-
els and patients (Hayek et al., 1998; Yusuf et al., 2000; Abd Alla
et al., 2004; Wassmann et al., 2004). DHE staining showed that
both treatment regimens normalized the increased superoxide
generation of atherosclerosis-prone ApoE−/− aortas. Superoxide
is the major vascular-damaging ROS triggered by angiotensin II
and drives the generation of other ROS such as hydrogen per-
oxide and peroxynitrite (Zafari et al., 1998; Touyz and Schiffrin,
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FIGURE 6 | Pro-inflammatory immune cell recruitment into the
atherosclerosis-prone aorta was sensitive to ACE inhibition but
insensitive to vitamin E treatment. (A) Microarray gene expression
data of probe sets detecting immune cell-specific markers are
presented as heat map centered to the median value. Data filtering and
GO analysis identified that genes marking T cells and macrophages
were significantly up-regulated in ApoE−/− aortas (≥2-fold; P < 0.05)
and normalized toward B6 control level by captopril treatment (ACE-I)
whereas genes marking B cells, which are considered atheroprotective,
were not significantly altered by ACE-inhibitor treatment. In contrast to
captopril, vitamin E treatment (VitE) did not reduce the expression of
pro-inflammatory immune cell-specific genes in the ApoE−/− aorta. (B)
Left panels: immunohistological detection of Ccr9-positive
aorta-infiltrating immune cells of a 32-week old ApoE−/− mouse and an
age-matched vitamin E-treated ApoE−/− mouse confirmed microarray
gene expression data. Ccr9-positive cells were not detected in the aorta
of a B6 control and an ACE-inhibitor-treated ApoE−/− mouse (bar:
25μm). The right panel shows quantitative evaluation of
immunohistology data from four mice each (±s.d.; n = 4; aP = 0.0004;
bP = 0.0001 vs. ApoE−/−). (C) Left panel: immunoblot quantification of
aortic Cd8b protein content of 32-week old ApoE−/− mice, age-matched
vitamin E-treated, or ACE-inhibitor-treated ApoE−/− mice, and B6
control mice (±s.d.; n = 4; aP = 0.0015; bP = 0.0009 vs. ApoE−/−). The
right panels show representative immunoblots.
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FIGURE 7 | ACE-inhibition prevented the atherosclerosis-related
down-regulation of perivascular nerve-specific genes of ApoE−/− mice.
(A) Microarray gene expression data of probe sets detecting aortic
nerve-specific genes, which were significantly down-regulated in ApoE−/−
aortas relative B6 controls, are presented as heat map centered to
(Continued)
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FIGURE 7 | Continued
the median value. Data filtering and GO analysis identified 30 significantly
down-regulated probe sets in ApoE−/− aortas relative to B6 controls
(P ≤ 0.01, and ≤−2-fold lower signal intensity) marking the neuronal
component (dendrites, myelin sheath, neuronal cell body) and/or the
process of nervous system development. Nerve-specific probe sets were
not significantly altered by vitamin E treatment (VitE) whereas captopril
treatment (ACE-I) normalized the expression of nerve-specific probe sets
toward B6 control level. (B) Validation of aortic microarray data by
quantitative immunoblot analysis of the aortic content of
synaptosomal-associated 25 kDa protein, Snap25. The upper panel presents
quantitative immunoblot data (±s.d.; n = 4; aP = 0.0034; bP = 0.0090), and
middle and lower panels show representative immunoblots. (C) Left panels:
Immunohistological detection of neuropeptide Y (Npy) showed
down-regulation of Npy-positive neurons in the ascending aorta of an
ApoE−/− mouse relative to the B6 control (upper panels). Vitamin E
treatment (VitE) did not substantially prevent the down-regulation of
Npy-positive neurons whereas captopril (ACE-I) treatment prevented the
decrease in Npy-positive immunoreactivity in the aorta of an ApoE−/−
mouse (bar: 100μm; nuclei were counterstained with hematoxylin, HE).
The right panel shows quantitative evaluation of immunohistology data
from four mice each (±s.d.; n = 4; aP = 0.0075; bP = 0.0095 vs. ApoE−/−).
2001; Guzik and Harrison, 2006; Pacher et al., 2007) Therefore,
comparable superoxide reduction indicates overlapping antioxi-
dant effects of vitamin E and the ACE inhibitor, captopril. While
we detected comparable antioxidant effects of vitamin E and
captopril, ACE inhibition wasmore effective in slowing the devel-
opment of atherosclerotic plaques, i.e., vitamin E treatment for
7 months retarded atherosclerotic lesion development by 45.8 ±
11.5% whereas the atherosclerotic plaque area of captopril-
treated aortas was reduced by 88.1 ± 7.5%. That observation
strongly suggests that ACE inhibition could exert ROS-dependent
and ROS-independent anti-atherogenic effects.
To identify atherosclerosis-related pathomechanisms with
concordant sensitivity to vitamin E treatment and ACE inhibi-
tion, we performed whole genome microarray gene expression
profiling of aortic genes. Searching for significantly altered probe
sets with concordant regulation between vitamin E and capto-
pril, we found that more than 82% of those concordantly regu-
lated probe sets were normalized toward B6 control level. Since
treatment-related normalization toward B6 control level could
indicate a potential involvement in atherosclerosis lesion develop-
ment, we focused on those probe sets with concordant regulation
between vitamin E and captopril, which showed normalization
toward B6 control level.
GO analysis of probe sets with significantly higher expres-
sion after treatment compared to untreated ApoE−/− aortas
and immunohistology analysis revealed that vitamin E treatment
and ACE inhibition prevented the atherosclerosis-related down-
regulation of aortic intima genes of ApoE−/− mice. Identified
aortic intima genes such as Sprr3 were previously associated with
stratified epithelium, and considered to strengthen the aortic
intima against biomechanical stress (Young et al., 2005). In this
respect our findings are complementary to recent observations,
which indicated that ROS is involved in the degeneration of the
aortic intima by enhancing the development of endothelial dys-
function (Guzik and Harrison, 2006). Underlying mechanisms
could involve inactivation of the atheroprotective nitric oxide
(NO), reduced NO synthesis and/or eNOS uncoupling (Li and
Förstermann, 2009). Since angiotensin II-induced activation of
NADPH oxidases in endothelial cells is an important contributor
to the generation of ROS in the vasculature (Chalupsky and Cai,
2005; Doughan et al., 2008), our microarray study strongly sug-
gests that angiotensin II-stimulated ROS generation could exert
a substantial role in deteriorating the endothelial layer, although
the precise role of identified genes in atherogenesis remains to be
determined.
GO analysis of probe sets with significantly lower expression
upon treatment compared to untreated ApoE−/− aortas detected
that vitamin E and ACE inhibition prevented the up-regulation
of muscle-specific genes in the atherosclerosis-prone aorta of
ApoE−/− mice. Immunohistology analysis confirmed this find-
ing and showed that up-regulation of muscle-specific genes such
as phospholamban in the aortic media correlated with the prolif-
eration of smooth muscle cells close to atherosclerotic plaques, a
process, which marks the transition of the contractile to the syn-
thetic phenotype of vascular smooth muscle cells. Since the initial
discovery by Griendling et al. (1994), the involvement of ROS-
induced angiotensin II generation in proliferation of smooth
muscle cells and vascular hypertrophy is supported by numer-
ous in vitro and in vivo studies (Garrido and Griendling, 2009).
Our findings complement those studies by showing that vita-
min E treatment and ACE inhibition mediated similar effects
concerning the protection of the aortic intima and media in
atherosclerosis-prone ApoE−/− mice. Taken together, our find-
ings are compatible with the concept that ROS aggravates the
pathogenesis of atherosclerosis. However, the sole inhibition
of angiotensin II-induced and NADPH-dependent generation of
ROS does not seem sufficient to prevent the development of
atherosclerosis (Schramm et al., 2012). Therefore, ACE inhibi-
tion could exert additional anti-atherogenic activities. Such anti-
atherogenic effects of angiotensin II inhibition seem to be largely
blood pressure-independent because lowering of blood pressure
without angiotensin II inhibition, e.g., by hydralazine, did not
reduce atherosclerotic lesion area of ApoE−/− mice (Hayek et al.,
1999).
In search for additional, vitamin E-independent mechanisms,
which could contribute to the anti-atherogenic potential of ACE
inhibitors, we focused on the activity of angiotensin II to pro-
mote the aortic recruitment of pro-inflammatory immune cells
(Abd Alla et al., 2004; Cassis et al., 2007; Fukuda et al., 2008). The
microarray study and immune techniques demonstrated and con-
firmed that angiotensin II inhibition reduced the aortic recruit-
ment of pro-inflammatory immune cells (Abd Alla et al., 2010).
While the atherosclerosis-promoting activity of angiotensin II-
stimulated aortic immune cell recruitment is firmly established
(Abd Alla et al., 2004, 2010; Cassis et al., 2007; Fukuda et al.,
2008), our current microarray study revealed that the aortic
recruitment of pro-inflammatory cells was apparently insensi-
tive to vitamin E treatment because vitamin E did not prevent
the atherosclerosis-related increase of immune-cell specific gene
expression in the aorta. Since pro-inflammatory immune cells
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exert a substantial role in atherogenesis (Ross, 1999; Hansson and
Libby, 2006), the latter observation could—at least partially—
explain major differences in the anti-atherogenic activity of ACE
inhibition relative to vitamin E treatment observed in animal
models and patients.
In addition to inflammatory immune cell migration, which is
a well-established factor in atherogenesis, whole genomemicroar-
ray gene expression profiling revealed another, largely unrec-
ognized atherosclerosis-related process in ApoE−/− mice, i.e.,
the degeneration of perivascular nerves of the aortic adventi-
tia. Notably, the atherosclerosis-prone aorta of ApoE−/− mice
was characterized by a significant down-regulation of multi-
ple nerve-specific genes. Down-regulation of neuronal genes
could affect sympathetic nerves, as reflected by down-regulation
of Ddc, Dbh, the norepinephrine transporter Slc6a2, and
the sympathetic nerve-associated Npy. Immunohistology con-
firmed gene expression data and showed that Npy-positive neu-
rons were significantly decreased in the aortic adventitia of
ApoE−/− mice.
Down regulation of perivascular nerve gene expression was
largely prevented by ACE inhibition with captopril. In con-
trast, down-regulation of neuronal genes was not substantially
affected by vitamin E treatment. These findings could indicate
that perivascular nerve degeneration in atherosclerosis could be
promoted by excessive angiotensin II generation. Since perivas-
cular nerve degeneration of spontaneously hypertensive rats was
also prevented by angiotensin II inhibition (Hobara et al., 2005),
angiotensin II and/or high blood pressure seem to exert a com-
mon nerve-degenerating effect in the cardiovascular system. In
agreement with that notion, perivascular nerve deficits and/or
degeneration were detected in different cardiovascular diseases
with exaggerated angiotensin II generation such as hypertension,
diabetes, and atherosclerosis (Webster et al., 1991; Scott et al.,
1992; Verbeuren et al., 1994; Hobara et al., 2005). At present,
the pathophysiological role of perivascular nerve degeneration
is not fully understood, and additional research in this area is
urgently needed. However, some previous studies indicated that
the atherosclerosis-related degeneration of perivascular nerves,
notably a local decrease in sympathetic nervous activity, could
render the vasculature more susceptible to atherosclerosis by
increasing the accumulation of collagen and lipids in the vessel
wall (Fronek and Turner, 1980), and reducing the adaptive-
trophic influence of sympathetic nerves on vascular structure
(Bevan, 1984; Shvalev et al., 1996).
Taken together our study showed that the anti-atherogenic
potential of ACE inhibition could be partially attributed to
antioxidant vitamin E-like effects in the aortic intima and media.
However, major atherosclerosis-related activities of angiotensin II
inhibition were not sensitive to vitamin E treatment such as pre-
vention of aortic recruitment of pro-inflammatory immune cells
and degeneration of perivascular nerves. Those major differences
between ACE inhibition and vitamin E treatment could account
for the documented anti-atherogenic activity of ACE inhibitors in
patients compared to the weak effect of vitamin E.
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